373 related articles for article (PubMed ID: 20399700)
1. Impact of tumor microenvironment on oncolytic viral therapy.
Wojton J; Kaur B
Cytokine Growth Factor Rev; 2010; 21(2-3):127-34. PubMed ID: 20399700
[TBL] [Abstract][Full Text] [Related]
2. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
3. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses for induction of anti-tumor immunity.
Tong AW; Senzer N; Cerullo V; Templeton NS; Hemminki A; Nemunaitis J
Curr Pharm Biotechnol; 2012 Jul; 13(9):1750-60. PubMed ID: 21740355
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
8. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
10. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
[TBL] [Abstract][Full Text] [Related]
11. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
[TBL] [Abstract][Full Text] [Related]
12. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
13. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.
Yun CO
Curr Opin Mol Ther; 2008 Aug; 10(4):356-61. PubMed ID: 18683100
[TBL] [Abstract][Full Text] [Related]
15. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?
Naik JD; Twelves CJ; Selby PJ; Vile RG; Chester JD
Clin Cancer Res; 2011 Jul; 17(13):4214-24. PubMed ID: 21576084
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
17. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
19. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
20. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
